Biosimilars are saving money but not in the U.S., where companies have used a variety of stalling tactics. Now Pfizer and others are accusing Johnson & Johnson of withholding rebates to fend off biosimilar competition to Remicade.
The TNF-α blocker is the world’s top-selling drug, by revenue. It faces biosimilar competition in Europe, but it will be four years before it’s challenged in the U.S.
The price of biologics can ruin cancer patients financially, this leading oncology expert reminds us. Biosimilars may help, but we need more of them on the market.

16 FDA-approved Biosimilars

Shaded rows indicate products on the market as of Jan. 14, 2019

  1. Herzuma (trastuzumab-pkrb, Celltrion and Teva)
  2. Truxima (rituximab-abbs, Celltrion)
  3. Udenyca (pegfilgrastim-cbqv, Coherus BioSciences)
  4. Hyrimoz (adalimumab-adaz, Sandoz)
  5. Nivestym (filgrastim-aafi, Pfizer)
  6. Fulphila (pegfilgrastim-jmdb, Mylan)
  7. Retacrit (epoetin alfa-epbx, Hospira*)
  8. Ixifi (infliximab-qbtx, Pfizer)
  9. Ogivri (trastuzumab-dkst, Mylan)
  10. Mvasi (bevacizumab-awwb, Amgen)
  11. Cyltezo (adalimumab-adbm, Boehringer Ingelheim)
  12. Renflexis (infliximab-abda, Merck)
  13. Amjevita (adalimumab-atto, Amgen)
  14. Erelzi (etanercept-szzs, Sandoz)
  15. Inflectra (infliximab-dyyb, Celltrion and Pfizer)
  16. Zarxio (filgrastim-sndz, Sandoz)

*Hospira is a subsidiary of Pfizer.

Our most popular topics on